insights_auto
Why is ABVX down ३.६७%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
€ ७८.७०
arrow_downward
-३.६७%(-३.००) 1D
अक्टोबर २३, १७:३५:२७ GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€ ८०.९०
High
€ ८१.१५
Low
€ ७८.०५
Mkt. cap
६.९६ अरब
Avg. vol.
१.२५ लाख
Volume
७४.८७ हजार
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
Open
€ ८०.९०
High
€ ८१.१५
Low
€ ७८.०५
Mkt. cap
६.९६ अरब
Avg. vol.
१.२५ लाख
Volume
७४.८७ हजार
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
Yahoo Finance
·
५४ मिनेट पहिले
Snowflake CMO NYSE Setting is 'Huge Inspiration' for Startup Campaign Finalists
CNBC
·
१ घण्टा पहिले
The S&P 500 is forming a bearish chart pattern. Can it snap out of it?
Business Insider
·
१ घण्टा पहिले
The Dow plunges 500 points as fears of renewed Middle East fighting send oil soaring
The New York Times
·
५ घण्टा पहिले
A Tech Rotation Roils the Markets, Again
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
Sector-
Websiteabivax.com